Beta Bionics [BBNX] vs Abbott Laboratories [ABT] Detailed Stock Comparison
Beta Bionics
NASDAQ
Loading...
Abbott Laboratories
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Beta Bionics wins in 4 metrics, Abbott Laboratories wins in 13 metrics, with 0 ties. Abbott Laboratories appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Beta Bionics | Abbott Laboratories | Better |
|---|---|---|---|
| P/E Ratio (TTM) | -17.42 | 16.89 | Beta Bionics |
| Price-to-Book Ratio | 3.21 | 4.63 | Beta Bionics |
| Debt-to-Equity Ratio | 2.22 | 26.50 | Beta Bionics |
| PEG Ratio | 3.90 | 0.46 | Abbott Laboratories |
| EV/EBITDA | -11.82 | 21.02 | Beta Bionics |
| Profit Margin (TTM) | -94.04% | 32.43% | Abbott Laboratories |
| Operating Margin (TTM) | -85.52% | 19.73% | Abbott Laboratories |
| EBITDA Margin (TTM) | N/A | 19.73% | N/A |
| Return on Equity | 22.32% | 30.93% | Abbott Laboratories |
| Return on Assets (TTM) | -36.59% | 6.62% | Abbott Laboratories |
| Free Cash Flow (TTM) | $-51.67M | $6.35B | Abbott Laboratories |
| Dividend Yield | N/A | 1.28% | N/A |
| 1-Year Return | -6.51% | 19.49% | Abbott Laboratories |
| Price-to-Sales Ratio (TTM) | 12.40 | 5.43 | Abbott Laboratories |
| Enterprise Value | $724.61M | $240.70B | Abbott Laboratories |
| EV/Revenue Ratio | 9.29 | 5.58 | Abbott Laboratories |
| Gross Profit Margin (TTM) | 53.80% | 56.44% | Abbott Laboratories |
| Revenue per Share (TTM) | $4 | $25 | Abbott Laboratories |
| Earnings per Share (Diluted) | $-1.69 | $7.97 | Abbott Laboratories |
| Beta (Stock Volatility) | N/A | 0.70 | N/A |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Beta Bionics vs Abbott Laboratories Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Beta Bionics | -1.39% | 13.98% | 13.11% | 64.64% | 106.69% | -5.80% |
| Abbott Laboratories | -0.63% | 0.78% | 1.82% | 0.11% | 2.25% | 18.64% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Beta Bionics | -6.51% | -6.51% | -6.51% | -6.51% | -6.51% | -6.51% |
| Abbott Laboratories | 19.49% | 32.22% | 22.75% | 221.29% | 431.14% | 556.86% |
News Based Sentiment: Beta Bionics vs Abbott Laboratories
Beta Bionics
News based Sentiment: POSITIVE
Beta Bionics demonstrated strong Q2 earnings, exceeding expectations, and secured a significant analyst upgrade. While insider selling is a concern, the influx of institutional investment and strategic partnership with Abbott suggest a positive trajectory for the company, making this a noteworthy month for investors.
Abbott Laboratories
News based Sentiment: POSITIVE
Abbott Laboratories reported strong Q2 2025 earnings and raised its full-year guidance, leading to positive analyst upgrades and increased institutional investment. While the ongoing NEC litigation presents a risk, the overall narrative is positive, suggesting continued growth and profitability for the company.
Performance & Financial Health Analysis: Beta Bionics vs Abbott Laboratories
| Metric | BBNX | ABT |
|---|---|---|
| Market Information | ||
| Market Cap | $1.10B | $234.39B |
| Market Cap Category | Small cap | Mega cap |
| 10 Day Avg. Volume | 803,623 | 5,683,430 |
| 90 Day Avg. Volume | 938,151 | 5,498,563 |
| Last Close | $21.95 | $133.74 |
| 52 Week Range | $8.89 - $26.66 | $110.86 - $141.23 |
| % from 52W High | -17.67% | -5.30% |
| All-Time High | $26.66 (Sep 12, 2025) | $142.60 (Dec 27, 2021) |
| % from All-Time High | -17.67% | -6.21% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.54% | 0.07% |
| Quarterly Earnings Growth | 0.80% | 0.37% |
| Financial Health | ||
| Profit Margin (TTM) | -0.94% | 0.32% |
| Operating Margin (TTM) | -0.86% | 0.20% |
| Return on Equity (TTM) | 0.22% | 0.31% |
| Debt to Equity (MRQ) | 2.22 | 26.50 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $6.94 | $29.05 |
| Cash per Share (MRQ) | $5.75 | $4.18 |
| Operating Cash Flow (TTM) | $-57,461,000 | $9.04B |
| Levered Free Cash Flow (TTM) | $-54,756,000 | $5.92B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 1.28% |
| Last 12-Month Dividend | N/A | $1.69 |
Valuation & Enterprise Metrics Analysis: Beta Bionics vs Abbott Laboratories
| Metric | BBNX | ABT |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | -17.42 | 16.89 |
| Forward P/E | -12.39 | 26.08 |
| PEG Ratio | 3.90 | 0.46 |
| Price to Sales (TTM) | 12.40 | 5.43 |
| Price to Book (MRQ) | 3.21 | 4.63 |
| Market Capitalization | ||
| Market Capitalization | $1.10B | $234.39B |
| Enterprise Value | $724.61M | $240.70B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 9.29 | 5.58 |
| Enterprise to EBITDA | -11.82 | 21.02 |
| Risk & Other Metrics | ||
| Beta | N/A | 0.70 |
| Book Value per Share (MRQ) | $6.94 | $29.05 |
Financial Statements Comparison: Beta Bionics vs Abbott Laboratories
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | BBNX | ABT |
|---|---|---|
| Revenue/Sales | $17.64M | $10.36B |
| Cost of Goods Sold | $8.67M | $4.47B |
| Gross Profit | $8.97M | $5.89B |
| Research & Development | $7.59M | $716.00M |
| Operating Income (EBIT) | $-18.64M | $1.69B |
| EBITDA | $-5.59M | $2.66B |
| Pre-Tax Income | $-28.66M | $1.78B |
| Income Tax | N/A | $453.00M |
| Net Income (Profit) | $-28.66M | $1.33B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | BBNX | ABT |
|---|---|---|
| Cash & Equivalents | $42.45M | $6.53B |
| Total Current Assets | $261.92M | $23.15B |
| Total Current Liabilities | $16.49M | $13.00B |
| Long-Term Debt | $5.45M | $12.74B |
| Total Shareholders Equity | $313.75M | $49.06B |
| Retained Earnings | $-325.39M | $47.72B |
| Property, Plant & Equipment | $13.04M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | BBNX | ABT |
|---|---|---|
| Operating Cash Flow | $-24.83M | $1.42B |
| Capital Expenditures | $-333,000 | $-484.00M |
| Free Cash Flow | $-20.31M | $933.00M |
| Debt Repayment | N/A | $-1.00B |
| Common Stock Repurchase | N/A | $-280.00M |
Short Interest & Institutional Ownership Analysis
| Metric | BBNX | ABT |
|---|---|---|
| Shares Short | 3.88M | 18.07M |
| Short Ratio | 5.52 | 3.68 |
| Short % of Float | 0.10% | 0.01% |
| Average Daily Volume (10 Day) | 803,623 | 5,683,430 |
| Average Daily Volume (90 Day) | 938,151 | 5,498,563 |
| Shares Outstanding | 42.86M | 1.73B |
| Float Shares | 21.42M | 1.73B |
| % Held by Insiders | 0.01% | 0.01% |
| % Held by Institutions | 1.09% | 0.81% |
Dividend Analysis & Yield Comparison: Beta Bionics vs Abbott Laboratories
| Metric | BBNX | ABT |
|---|---|---|
| Last 12-Month Dividend | N/A | $1.69 |
| Last 12-Month Dividend Yield | N/A | 1.28% |
| 3-Year Avg Annual Dividend | N/A | $1.92 |
| 3-Year Avg Dividend Yield | N/A | 0.49% |
| 3-Year Total Dividends | N/A | $5.77 |
| Ex-Dividend Date | N/A | Jan 15, 2025 |